Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine
- PMID: 18018769
Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine
Abstract
Background: Emergence of severe acute respiratory syndrome (SARS) from the winter of 2002 to the spring of 2003 has caused a serious threat to public health.
Methods: To evaluate the safety and immunogenicity of the inactivated SARS coronavirus (SARS-CoV) vaccine, 36 subjects received two doses of 16 SARS-CoV units (SU) or 32 SU inactivated SARS-CoV vaccine, or placebo control.
Results: On day 42, the seroconversion reached 100% for both vaccine groups. On day 56, 100% of participants in the group receiving 16 SU and 91.1% in the group receiving 32 SU had seroconverted. The geometric mean titre of neutralizing antibody peaked 2 weeks after the second vaccination, but decreased 4 weeks later.
Conclusion: The inactivated vaccine was safe and well tolerated and can elicit SARS-CoV-specific neutralizing antibodies.
Similar articles
-
SARS Immunity and Vaccination.Cell Mol Immunol. 2004 Jun;1(3):193-8. Cell Mol Immunol. 2004. PMID: 16219167 Review.
-
A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.Vaccine. 2006 Jan 30;24(5):652-61. doi: 10.1016/j.vaccine.2005.08.055. Epub 2005 Aug 26. Vaccine. 2006. PMID: 16214268 Free PMC article.
-
Humoral immune responses in rabbits induced by an experimental inactivated severe acute respiratory syndrome coronavirus vaccine prepared from F69 strain.Chin Med J (Engl). 2004 Nov;117(11):1625-9. Chin Med J (Engl). 2004. PMID: 15569476
-
Immunogenicity of SARS inactivated vaccine in BALB/c mice.Immunol Lett. 2004 Sep;95(2):139-43. doi: 10.1016/j.imlet.2004.06.014. Immunol Lett. 2004. PMID: 15388253 Free PMC article.
-
Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus.Avian Pathol. 2003 Dec;32(6):567-82. doi: 10.1080/03079450310001621198. Avian Pathol. 2003. PMID: 14676007 Free PMC article. Review.
Cited by
-
A Cocktail of Lipid Nanoparticle-mRNA Vaccines Broaden Immune Responses against β-Coronaviruses in a Murine Model.Viruses. 2024 Mar 21;16(3):484. doi: 10.3390/v16030484. Viruses. 2024. PMID: 38543849 Free PMC article.
-
Could SARS-CoV-1 Vaccines in the Pipeline Have Contributed to Fighting the COVID-19 Pandemic? Lessons for the Next Coronavirus Plague.Biomedicines. 2023 Dec 27;12(1):62. doi: 10.3390/biomedicines12010062. Biomedicines. 2023. PMID: 38255169 Free PMC article.
-
Immunoinformatics lessons on the current COVID-19 pandemic and future coronavirus zoonoses.Front Immunol. 2023 Dec 12;14:1118267. doi: 10.3389/fimmu.2023.1118267. eCollection 2023. Front Immunol. 2023. PMID: 38149247 Free PMC article. No abstract available.
-
HIV infection and the implication for COVID-19 vaccination.Public Health Chall. 2022 Sep;1(3):e14. doi: 10.1002/puh2.14. Epub 2022 Jul 29. Public Health Chall. 2022. PMID: 37521727 Free PMC article. Review.
-
Prime-boost, double-dose influenza vaccine immunity in COPD: a pilot observational study.ERJ Open Res. 2023 Mar 6;9(2):00641-2021. doi: 10.1183/23120541.00641-2021. eCollection 2023 Mar. ERJ Open Res. 2023. PMID: 36891079 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous